Pemason Pharma Sponsors Drug Information Publication - EMDEX 2018-2019 Edition

Pemason Pharma Sponsors Drug Information Publication - EMDEX 2018-2019 Eition  Publication of drug information is a costly costly operation, made made more more challenging in a harsh economic economic and resource-limited setting like the sub-Saharan Africa. To sustain its yearly updates and digitize the print editions, EME! needed a lifeline in form of sponsorship. sponsorship. Pemason, "igeria#s "igeria#s leading  pharmaceutical  pharmaceutical firm, promptly promptly said yes to the initiati$e. The outcome outcome is the onset onset of a uni%ue  partnership that that can potentially change change the face of of healthcare healthcare in the region. region.

!agos" #igeria$" #o%ember 0&" 201' -- EMDEX Limited is pleased pleased to announce announce the Corporate Sponsor for EMDEX 2018-2019 Edition – EM!S"# $!%M!CE&'(C!LS $!%M!CE&'(C!LS L(M('ED) 'he compan* has an e+tensi,e portfolio of medicines co,erin e,er* ma.or indication area such as Micropirin/ emametre and etaren) &nder this ne fundin arranement/ emason harma is pro,idin the much-needed funds to help ith EMDEX Dru (nformation updates and the onoin de,elopment of the diital editions) (n return/ emason ill enefit from increased ,isiilit* of their rands under special promotional arranement on all EMDEX platforms namel* the rint/ "nline 3 Moile) 4hat does this mean for the healthcare sector5  6! lot) (t is a in-in situation for all parties) !ccess !ccess to 7ualit* dru information for healthcare professionals ill translate to etter therapeutic decisions and positi,e dru therap* outcomes for the patient/ said Chris C) "i/ ounder of EMDEX) 6* committin more funds to EMDEX or:/ emason harma is demonstratin their leadership in oth 7ualit* medicines and patient care) !nd our e+pectation is that other companies ill see this as an opportunit* to ma:e a difference EMDEX 2018 ill e focusin on Dru Safet* ith e+tended co,erae of arameters for Monitorin 3 atient Education) (nteraction Chec:er is another onoin pro.ect that ill enefit from this fundin areement) 6'he strenth of emason harmaceuticals Ltd lies in the 7ualit* of our products and the hori;ontal manaement structure that allos for free flo of information as ell as input * e,er* staff/ said harm) atric: ") "sele/ CE" of emason/ in a statement released * the compan*) compan*) 6"ur oal is to ma:e the patient the center-point of healthcare deli,er* s*stem hile ma:in a name ith 7ualit* EMDEX s Essential Drus List/ EMDEX is uni7ue to #ieria as it also details mainl* the pharmaceuticals and allied products appro,ed for use in the countr*)

(ontact) Chris C) "i EMDEX #o) 2?/ "solo 4a* !.ao Estate/ Laos State/ #ieria @1-A1B-?2B-A2A? editoremde+online)com https)emde+online)com